Gilead Sciences Inc (GILD) Growth Rates Comparisons to Biotechnology & Pharmaceuticals Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Industry, else..
 
Gilead Sciences Inc   (NASDAQ: GILD)
 

Gilead Sciences Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GILD Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) 10.18 % 5.15 % 10.17 % 10.9 %
Q / Q Revenue Growth (Q2 MRQ) 12.11 % -11.92 % -2.4 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) 5.52 % 5.66 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) 2.42 % 1.16 % 2.09 % 2.61 %
Revenue 5 Year Average Growth 3.58 % 8.2 % 8.7 % 13.64 %


GILD's Growth Comparisons in II. Quarter 2026




Gilead Sciences Inc improved it's Revenue by 10.18% year on year in the second quarter 2026, and outpaced the 5.15% growth in the Biotechnology & Pharmaceuticals industry, and 10.17% improvement in the Healthcare sector.

Top-line improved by 12.11% from the first quarter. Looking into annual sales rise of 3.58%, and S & P 500's average yearly sales growth is 13.64% over the five years, including only Businesses with the second quarter 2026 Results. Gilead Sciences Inc grew less than the market.

GILD Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
U S
5.53 %
-
Europe
5.54 %
-
Rest of World
-2.84 %
-
Total product sales
5.04 %
-
Total product sales U S
6.37 %
-
Total product sales Europe
5.96 %
-
Total product sales Rest of World
-2.86 %
-
Total HIV
9.66 %
-
Total HIV U S
9.28 %
-
Total HIV Europe
9.76 %
-
Total HIV Rest of World
13.24 %
-
Biktarvy
6.7 %
-
Biktarvy U S
4 %
-
Biktarvy Europe
16.53 %
-
Biktarvy Rest of World
16.94 %
-
Descovy
37.71 %
-
Descovy U S
41.45 %
-
Descovy Europe
9.52 %
-
Descovy Rest of World
-14.81 %
-
Genvoya
-27.47 %
-
Genvoya U S
-29.51 %
-
Genvoya Europe
-17.5 %
-
Genvoya Rest of World
-15.79 %
-
Odefsey
-21.35 %
-
Odefsey U S
-28.84 %
-
Odefsey Europe
3.51 %
-
Odefsey Rest of World
-10 %
-
Symtuza - Revenue share
21.05 %
-
Symtuza - Revenue share U S
30.49 %
-
Symtuza - Revenue share Europe
-3.45 %
-
Symtuza - Revenue share Rest of World
0 %
-
Yeztugo
-
-
Yeztugo U S
-
-
Yeztugo Rest of World
-
-
Other HIV
-19.78 %
-
Other HIV U S
-28 %
-
Other HIV Europe
-12.9 %
-
Other HIV Rest of World
-10 %
-
Total Oncology
7 %
-
Total Oncology U S
5.77 %
-
Total Oncology Europe
9.02 %
-
Total Oncology Rest of World
6.61 %
-
Total Cell Therapy
-12.28 %
-
Total Cell Therapy U S
-25 %
-
Total Cell Therapy Europe
1.67 %
-
Total Cell Therapy Rest of World
-11.9 %
-
Tecartus
-3.85 %
-
Tecartus U S
-25 %
-
Tecartus Europe
19.35 %
-
Tecartus Rest of World
0 %
-
Yescarta
-13.99 %
-
Yescarta U S
-25 %
-
Yescarta Europe
-2.01 %
-
Yescarta Rest of World
-12.99 %
-
Trodelvy
37.2 %
-
Trodelvy U S
39.78 %
-
Trodelvy Europe
26.67 %
-
Trodelvy Rest of World
45.95 %
-
Total Liver Disease
1.19 %
-
Total Liver Disease U S
8.06 %
-
Total Liver Disease Europe
1.19 %
-
Total Liver Disease Rest of World
-8.2 %
-
Livdelzi
232.5 %
-
Livdelzi U S
187.5 %
-
Livdelzi Europe
-
-
Sofosbuvir Velpatasvir
-18.21 %
-
Sofosbuvir Velpatasvir U S
-15.06 %
-
Sofosbuvir Velpatasvir Europe
-25 %
-
Sofosbuvir Velpatasvir Rest of World
-17.17 %
-
Vemlidy
-5.95 %
-
Vemlidy U S
-9 %
-
Vemlidy Europe
8.33 %
-
Vemlidy Rest of World
-5.71 %
-
Other Liver Disease
-5.79 %
-
Other Liver Disease U S
-46.43 %
-
Other Liver Disease Europe
2.63 %
-
Other Liver Disease Rest of World
23.53 %
-
Veklury
-52.32 %
-
Veklury U S
-43.72 %
-
Veklury Europe
-36.36 %
-
Veklury Rest of World
-78.05 %
-
Total Other
-6.22 %
-
Total Other U S
-11.54 %
-
Total Other Europe
-11.84 %
-
Total Other Rest of World
2.47 %
-
AmBisome
-0.72 %
-
AmBisome U S
40 %
-
AmBisome Europe
-11.94 %
-
AmBisome Rest of World
9.09 %
-
Other
-17.14 %
-
Other U S
-17.02 %
-
Other Europe
-11.11 %
-
Other Rest of World
-21.43 %
-
Royalty contract and other revenues
-74.07 %
-
Royalty contract and other revenues Europe
-27.27 %
-
Royalty contract and other revenues Rest of World
0 %
-
Total
4.39 %
-


Growth Rates of GILD's Income in the second quarter 2026


GILD Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) - 440.4 % 11.42 % 97.6 %
Sequential Operating Income Change (Q2 MRQ) - -48.71 % -12.77 % 48.13 %
Y / Y Operating Income Growth (Q2 TTM) - 997.37 % 30.99 % 40.67 %
Sequential Operating Income Growth (Q2 TTM) - 229.64 % 4.94 % 20.86 %
Operating Income 5 Year Avg. Change 19.74 % -18.52 % 10.27 % 18.8 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) - -78.38 % -14.37 % 90.69 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) - - -63.62 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) - -86.28 % 9.88 % 57.33 %
Sequential Income from Cont. Ops. Change (Q2 TTM) - -58.33 % -4.66 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change 148.95 % -11.53 % 8.91 % -28.64 %

GILD Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) - -79.71 % -15.01 % 90.69 %
Q / Q Net Income Growth (Q2 MRQ) - -87.33 % 11.25 % 27.07 %
Y / Y Net Income Change (Q2 TTM) - 103.17 % 15.48 % 57.33 %
Sequential Net Income Change (Q2 TTM) - -7.85 % -6.7 % 18.65 %
Net Income 5 Year Avg. Growth 148.95 % -8.7 % 9.08 % 23.91 %

GILD's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) - -81.71 % -14.37 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) - - -63.62 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) - - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth 132.82 % 49.27 % 8.91 % -28.64 %



GILD EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) - -82.83 % -15.01 % -28.64 %
Q / Q EPS Net Growth (Q2 MRQ) - -88.8 % 11.25 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) - - -4.12 % 4.93 %
EPS Net 5 Year Avg. Change 132.41 % -8.7 % 9.08 % 23.91 %



Gilead Sciences Inc reported bottom-line of $ -8.45 in the second quarter, compare to $ 1.56 in the same quarter a year ago. Biotechnology & Pharmaceuticals industry fell by -82.83%, while Healthcare sector decreased by -15.01%, and overall market improved by 90.69%.

The bottom-line improved by 12.11% from the first quarter. Looking into annual income per share rise of 132.41%, and S & P 500's average yearly income per share growth is 23.91% over the five years, including only Businesses with the second quarter 2026 earnings reports. Gilead Sciences Inc grew faster than the market.

GILD Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) 376.81 % 6160.46 % 46.64 % 48.62 %
Sequential Free Cash Flow Change (Q2 MRQ) 41.45 % -53.57 % -41.09 % 34.18 %
Y / Y Free Cash Flow Change (Q2 TTM) 38.15 % 14.36 % 19.59 % 60.27 %
Sequential Free Cash Flow Change (Q2 TTM) 26.52 % 17.17 % 5.78 % 15.75 %
Free Cash Flow 5 Year Avg. Change 4.69 % -13.86 % 0.41 % 1.92 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q2 MRQ) - 36.63 % - 216.68 %
Y / Y Net Cash Flow Change (Q2 TTM) 4.81 % 783.99 % - 209.43 %
Sequential Net Cash Flow Change (Q2 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change - 23.25 % 6.46 % 1.07 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) 30.84 % 32.26 % 10.58 % 120.03 %
Sequential Capital Expenditures Change (Q2 MRQ) 19.66 % -1.95 % -19.64 % 36.87 %
Y / Y Capital Expenditures Change (Q2 TTM) 22.04 % -4.97 % 7.77 % 109.38 %
Sequential Capital Expenditures Change (Q2 TTM) 5.73 % 7.49 % 1.52 % 23.05 %
Capital Expenditures 5 Year Avg. Change -2.83 % 9.64 % 8.6 % 14.74 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.